The DRw6 Phenomenon in Renal Transplantation

  • G. F. J. Hendriks
Part of the Developments in Hematology and Immunology book series (DIHI, volume 10)


During the first 10 years, the selection of potential recipients of cadaveric renal grafts in Eurotransplant was based primarily on ABO-compatibility and matching for the HLA-A and HLA-B locus determinants (1). The beneficial effect of HLA-A and -B matching on kidney graft survival was strongest in male recipients lacking bloodgroup O (2). HLA-A and -B matching did not only improve long term graft survival but also patient survival (3), probably due to a lower amount of corticosteroids given during the first postoperative months (4). However, 5 years after transplantation, over 40% of poorly matched grafts (those with ≥ 2 A/B mismatches) are still functioning. These recipients seem to be low responders against foreign transplantation antigens present in the graft. Another explanation may be that these patients belong to the so-called corticosteroid-sensitive group in which renal graft prognosis is good (5). Nevertheless, one should avoid, if possible, a high number of HLA-A and -B mismatches because there is one report that recipients with long term survival of poorly matched grafts appear to be in a high risk group with respect to the evetual development of malignancies (6).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rood JJ van. A proposal for international cooperation in organ transplantation. Histocompatibility Testing, 1967: 451–2.Google Scholar
  2. 2.
    Opelz G, Terasaki PI. Influence of sex on histocompatibility matching in renal transplantation. Lancet 1977;i:419–21.CrossRefGoogle Scholar
  3. 3.
    Persijn GG, Cohen B, Lansbergen Q, et al. Effect of HLA-A and HLA-B matching on survival of grafts and recipients after renal transplantation. N Engl J Med 1982; 307: 905–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Hooff JP van, Es JP van, Persijn GG, et al. Cadaveric graft survival, clinical course, blood transfusions, HLA (A and B) match, and DR match in adult patients transplanted in one center. Proceedings EDTA Congress, Robinson BHB, Hawkins JB, Naik RB, eds. Tunbridge Wells UK, Pitman Med Publ Co Ltd, 1979: 359–65.Google Scholar
  5. 5.
    Dumble LJ, Clunie GJA, Macdonald M, Bowes G, Kincaid-Smith P. Prediction of renal allograft rejection response to steroids from ADCC response to in vitro steroids. Transplantation Proceedings 1983;15: 1145–7.Google Scholar
  6. 6.
    Birkeland SA. Malignant tumors in renal transplant patients; the scandia transplant material. Cancer 1983; 51: 1571–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Persijn GG. Immune modulation aspects of bloodtransfusion in transplantation practice. In: Smit Sibinga CTh, Das PC, Opelz G, eds. Transplantation and blood transfusion. The Hague: Martinus Nijhoff Publ. 1984: 43–56.CrossRefGoogle Scholar
  8. 8.
    Persijn GG, Leeuwen A van, Hoogeboom J, Gabb BW, Nagtegaal A, Rood JJ van. Matching for HLA antigens of A, B, and DR loci in renal transplantation by Eurotransplant. Lancet 1978;ii:1278–81.CrossRefGoogle Scholar
  9. 9.
    Berg B, Groth CG, Lundgren G, Möller E, Ringden 0, Wilczek H. Five-year experience with DR matching in cadaveric kidney transplantation. Transplantation Proceedings 1983; 15: 1132–5.Google Scholar
  10. 10.
    Opelz G, Terasaki PI. International study of histocompatibility in renal transplantation. Transplantation 1982;33, 1: 87–95.PubMedCrossRefGoogle Scholar
  11. 11.
    Jakobsen B, Langhoff E, Platz P, et al. The impact of HLA-DR compatibility on cadaver kidney graft survival in a prospective study with special emphasis on the quality of typing. Tissue Antigens 1984; 23: 94–104.PubMedCrossRefGoogle Scholar
  12. 12.
    Lehner T. The relationship between human helper and suppressor factors to a streptococcal protein antigen. J Immunology 1982; 129: 1936–40.Google Scholar
  13. 13.
    Baldwin WM, Claas FHJ, Es LA van, Rood JJ van, Paul LC, Persijn GG. Renal graft rejection and the antigenic anatomy of human kidneys. Proceedings of the thirteenth International Course on Transplantation and Clinical Immunology, Lyon 1981; 13: 140–6.Google Scholar
  14. 14.
    Darke C, Street J, Sargeant C, Dyer PA. HLA-DR antigens and properdin factor B allotypes in responders and non-responders to the Rhesus-D antigen. Tissue Antigens 1983; 21: 333–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Hendriks GFJ, Claas FHJ, Persijn GG, Witvliet MD, Baldwin W, Rood JJ van. HLA-DRw6 positive recipients are high responders in renal transplantation. Transplantation Proceedings 1983; 15: 1136–8.Google Scholar
  16. 16.
    Hendriks GFJ, Scheuder GMTh, Claas FHJ, et al. HLA-DRw6 and renal allograft rejection. Brit Med J 1983; 286: 85–7.CrossRefGoogle Scholar
  17. 17.
    Hoitsma HJ, Reekers P, Lier HJJ van, Rens JG van, Koene R. HLA-Drw6 and treatment of acute rejection with antithymocyte globulin in renal transplantation. Transplantation 1984, in press.Google Scholar
  18. 18.
    Soulilou JP, Bignon JD. Poor kidney graft survival in recipients with HLA-DRw6. N Engl J Ned 1983; 308: 969.Google Scholar
  19. 19.
    Schmidt P, Balcke P, Zazgornik J, et al. HLA-DRw6 matching and primary renal graft failure due to rejection. Lancet 1983;ii:1277CrossRefGoogle Scholar
  20. 20.
    Hendriks GFJ, Claas FHJ, Schreuder GMTh, et al. Influence of HLA-DRw6 and HLA-DR matching on kidney graft prognosis. Dialysis & Transplantation 1983; 12: 95–6.Google Scholar
  21. 21.
    Ray JG. NIH lymphocyte microcytotoxicity technique. NIAID manual of tissue typing techniques (DHEW publication no (NIH) 77–545) DHEW 1977: 32.Google Scholar
  22. 22.
    Rood JJ van, Leeuwen A van, Ploem JS. Simultaneous detection of two cell populations by two-colour fluorescence and application to the recognition of B-cell determinants. Nature 1976; 262: 795–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Schreuder GMTh, Parlevliet J, Termijtelen A, Rood JJ van. Reanalysis of the HLA-DRw6 complex. Tissue Antigens 1983; 21: 62–74.PubMedCrossRefGoogle Scholar
  24. 24.
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Brit J Cancer 1977; 35: 1–39.PubMedCrossRefGoogle Scholar
  25. 25.
    Duquesnoy RJ, Annen KB, Marrari MM, Kauffman jr HM. Association of MB compatibility with successfull intrafamilial kidney transplantation. N Eng J Med 1980; 302: 821–4.CrossRefGoogle Scholar
  26. 26.
    Nishimura Y, Sasazuki T. Suppressor T cells control the HLA linked low responsiveness to streptococcal antigen in man. Nature 1983; 302: 67–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Corte G, Moretta A, Cosulich ME, Ramarli D, Bargellese A. A monoclonal anti-DCl antibody selectively inhibits the generation of effector T cells mediating specific cytolytic activity. J Exp Med 1982; 156: 1539–44.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1984

Authors and Affiliations

  • G. F. J. Hendriks

There are no affiliations available

Personalised recommendations